Starpharma completes US New Drug Application for VivaGel BV
Filed with ASX · · 3 pages · English
Starpharma Holdings Limited on 6ix
Story so far
Earlier from Starpharma
- Starpharma receives $3.7M R&D tax incentive refund
- Starpharma to commence DEP cabazitaxel phase 1/2 trial
- VivaGel BV treatment clinical submission under rolling NDA
- NDA submission for VivaGel BV in the US
- VivaGel BV granted marketing approval in Australia
Later from Starpharma
- Appendix 4C - Quarterly Cashflow Report
- Mundipharma licenses Starpharmas VivaGel BV
- Starpharma licenses VivaGel BV to Mundipharma for Europe
- VivaGel BV NDA advances to next stage of FDA review
- Annual report and full year financial results
Follow Starpharma into a list and get an email when it puts out news.
Follow Starpharma